ReviewFrontiers in cellular and infection microbiology2026
Diagnostic tests for urinary tract infections and antimicrobial resistance-a reality check between diagnostic innovation and implementation: a critical narrative review.
Review in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Species-Level Reconfiguration and Retrospective Bridging Assessment of a Multiplex PCR Panel for Complicated and Recurrent Urinary Tract Infections.Current issues in molecular biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Urinary tract infections (UTIs) are a significant health concern worldwide, leading to substantial health and economic burden and contributing to the rise of antimicrobial resistance (AMR). Although there has been significant advancement in diagnostic technologies starting from conventional dipstick urinalysis to molecular assays and artificial intelligence (AI)-supported platforms, their clinical utility and impact still remain unclear. This is fundamentally due to the systemic barriers that hinder the implementation including cost, policy, and limitations to integrate into frontline healthcare and adoption by insurance agencies. This review focuses on critically reviewing UTI epidemiology, current and emerging diagnostics, and their significance in antimicrobial stewardship. We emphasise that bridging the gap between diagnostic innovation and clinical practice is essential to achieving meaningful milestones in AMR reduction. We are primarily arguing that addressing the policy inertia to diagnostic deployment with stewardship strategies is a crucial step for improving patient healthcare outcomes and preserving antimicrobial efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.